Table 1 Patient demographics at registry inclusion
Parametera | All patients | Patients ever treated with pirfenidoneb | |
|---|---|---|---|
(N = 277) | Yes (N = 233) | No (N = 44) | |
Male | 213 (76.9) | 181 (77.7) | 32 (72.7) |
White | 255 (92.1) | 219 (94.0) | 36 (81.8) |
Age, years | Mean 69.6 (SD 8.6) | Mean 69.4 (SD 8.5) | Mean 70.6 (SD 8.9) |
Smoking status | |||
 Never | 74 (26.7) | 65 (27.9) | 9 (20.5) |
 Current | 18 (6.5) | 15 (6.4) | 3 (6.8) |
 Former | 185 (66.8) | 153 (65.7) | 32 (72.7) |
Previous treatment for IPF other than pirfenidone | |||
 Nintedanib | 9 (3.3) | 4 (1.7) | 5 (11.4) |
 N-acetylcysteine | 68 (24.6) | 62 (26.6) | 6 (13.6) |
 Corticosteroids | 50 (18.1) | 46 (19.7) | 4 (9.1) |
 Azathioprine | 3 (1.1) | 2 (0.9) | 1 (2.3) |
 Ambrisentan | 1 (0.4) | 0 (0.0) | 1 (2.3) |
Supplemental oxygen use | 29 (10.5) | 25 (10.7) | 4 (9.1) |